National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$51.75
add to cart

Rights & Permissions

topleft topright

Microbial Status and Genetic Evaluation of Mice and Rats: Proceedings of the 1999 US/Japan Conference (2000)
Institute for Laboratory Animal Research (ILAR)

Citation Manager

. "Defining Phenotype in Genetically Engineered Mice." Microbial Status and Genetic Evaluation of Mice and Rats: Proceedings of the 1999 US/Japan Conference. Washington, DC: The National Academies Press, 2000.

Please select a format:

BibTeX EndNote RefMan


Page
130
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Microbial Status and Genetic Evaluation of Mice and Rats: PROCEEDINGS OF THE 1999 US/JAPAN CONFERENCE

Defining Phenotype in Genetically Engineered Mice

Norikazu Tamaoki

Tokai University School of Medicine

Kanagawa, Japan

INTRODUCTION

Genetically engineered mice have become popular tools in recent biomedical research. However, only a few among thousands of genetically engineered mice so far reported have been established as laboratory animals that have controlled quality and are being produced and used on a large scale. The aims of defining phenotype in genetically engineered mice are as follows: (1) to define clearly the difference between genetically engineered animals produced for the purpose of elucidating the function of a gene or genes in vivo and laboratory animals used as a tool for studying the mechanism of diseases or testing drugs in vivo; and (2) to define clearly the difference among “genotype, ” “phenotype,” and “dramatype.” Dramatype, which is an altered function of the organism induced by changes in the environment and phenomena seen in the disease state, is the most important characteristic of laboratory animals.

HISTORICAL DEVELOPMENT

The following two examples of genetically engineered mice have been developed as useful laboratory animals in the biomedical field: the TgPVR21 mouse (poliovirus receptor transgenic mouse) and the ras H2 mouse (human proto-ras transgenic mouse).

Page
130
Front Matter (R1-R16)
Opening Remarks, Judith Vaitukaitis (1-3)
Opening Remarks, Shin-Ichi Ota (4-5)
Introductory Comments on Microbiologic Testing of Laboratory Mice and Rats: Uniformity of Results (6-6)
Development of a Performance Assessment Program for Research Animal Diagnostic Laboratories and Defining Microbiologic Testing Standards (7-10)
Standardization of Rodent Health Surveillance: Regulation Versus Competition (11-15)
Factors Causing Difficulties in Uniformity of Results Among Testing Facilities in Microbiologic Monitoring of Laboratory Animals (16-20)
Necessity of Reexamining the Pathogenicity and Elimination of Parasites in Rats and Mice (21-26)
Emerging (and Reemerging) Viruses of Laboratory Mice and Rats (27-34)
Emerging Infections as a Cause of Concern (35-39)
Emerging Diseases in Mice and Rats (40-43)
Survey of Heliobacter Species in Laboratory Mice and Gerbils in Japan (44-46)
Genetic Evaluation of Outbred Rats (47-50)
Genetic Evaluation of Outbred Rats from the Breeder's Perspective (51-64)
Concept for Establishment of Rat Outbred Global Standard Strains (65-76)
Necessity of Genetic and Microbiologic Quality Network from the Pharmaceutical Industry's Perspective (77-84)
International Harmonization of Laboratory Animals (85-96)
Rat Genetics and Toxicology (97-104)
A Phenotype-driven Approach to the Molecular and Functional Analysis of the Mouse Genome (105-115)
Evaluation of Targeted Mutations (116-118)
Defining Behavioral Phenotypes in Transgenic and Knockout Mice (119-129)
Defining Phenotype in Genetically Engineered Mice (130-131)
Development of the Mouse Model Dramatype for Human Clinical Benefit (132-136)
Concluding Remarks (137-137)
Implication of Wild-derived Genes, Mitochondria, and Chromosomes in the Genetic Background of Mouse Models for Diseases and Biologic Functions (138-141)
Concluding Comments, John Strandberg (142-143)
Concluding Remarks, John Vandenbergh (144-146)
Appendix A (147-148)
Appendix B (149-150)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 130
Microbial Status and Genetic Evaluation of Mice and Rats: PROCEEDINGS OF THE 1999 US/JAPAN CONFERENCE Defining Phenotype in Genetically Engineered Mice Norikazu Tamaoki Tokai University School of Medicine Kanagawa, Japan INTRODUCTION Genetically engineered mice have become popular tools in recent biomedical research. However, only a few among thousands of genetically engineered mice so far reported have been established as laboratory animals that have controlled quality and are being produced and used on a large scale. The aims of defining phenotype in genetically engineered mice are as follows: (1) to define clearly the difference between genetically engineered animals produced for the purpose of elucidating the function of a gene or genes in vivo and laboratory animals used as a tool for studying the mechanism of diseases or testing drugs in vivo; and (2) to define clearly the difference among “genotype, ” “phenotype,” and “dramatype.” Dramatype, which is an altered function of the organism induced by changes in the environment and phenomena seen in the disease state, is the most important characteristic of laboratory animals. HISTORICAL DEVELOPMENT The following two examples of genetically engineered mice have been developed as useful laboratory animals in the biomedical field: the TgPVR21 mouse (poliovirus receptor transgenic mouse) and the ras H2 mouse (human proto-ras transgenic mouse).

OCR for page 131
Microbial Status and Genetic Evaluation of Mice and Rats: PROCEEDINGS OF THE 1999 US/JAPAN CONFERENCE TgPVR21 Mouse (Poliovirus Receptor Transgenic Mouse) 1990-1991: Establishment of human poliovirus receptor transgenic mice 1991-1993: Establishment as a laboratory animal (standardization of characters and successful large-scale production) and development of methods for neurovirulence testing and safety assurance by castration (Levenbook and Nomura 1997) 1993-1995: World Health Organization (WHO) collaborative study of TgPVR21, 1st phase 1995-1997: WHO collaborative study of TgPVR21, 2nd phase 1997-1999: WHO collaborative study of TgPVR21, 3rd phase 1999: Approval of neurovirulence test of oral poliovirus vaccine alternative for monkeys by WHO Expert Committee on Biological Standardization ras H2 Mouse (Human Proto-ras Transgenic Mouse) 1988: Establishment of human proto-ras gene transgenic mouse 1990-1992: Backcrossing and establishment of congenics 1992-1996: Validation study for carcinogenicity testing in Japan (Yamamoto and others 1998) 1996-1999: Validation study for rapid carcinogenicity testing in the United States, the European Union, and Japan CONCLUSIONS As shown above, establishment of a novel laboratory animal from a genetically engineered animal is a lengthy process and requires many steps as follows: (1) establishing of a genetically engineered animal; (2) phenotyping and selection of candidate animals; (3) study of functions in purpose-oriented environments or experimentation (dramatyping); and (4) establishment of a human disease model as a laboratory animal. REFERENCES Levenbook, I., and T. Nomura. 1997. Development of a neurovirulent testing system for oral poliovirus vaccine with transgenic mice. Lab. Anim. Sci. 47:118-120. Yamamoto, S., K. Urano, H. Koizumi, S. Wakana, K. Hioki, K. Mitsumori, Y. Kurokawa, Y. Hayashi, and T. Nomura. 1998. Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. Environ. Health Perspect. 106(Suppl 1):57-69.

Representative terms from entire chapter:

engineered mice